Greek rheumatoid arthritis patients have elevated levels of antibodies against antigens from Proteus mirabilis. 2017

Georgios Christopoulos, and V Christopoulou, and J G Routsias, and A Babionitakis, and C Antoniadis, and G Vaiopoulos
First Department of Internal Medicine, Laikon General Hospital, Athens University, Athens, Greece. drchristog@gmail.com.

Patients with rheumatoid arthritis (RA) from different ethnic groups present elevated levels of antibodies against Proteus mirabilis. This finding implicates P. mirabilis in the development of RA. The aim of this study was to investigate the importance of P. mirabilis in the etiopathogenesis of RA in Greek RA patients. In this study, 63 patients with RA and 38 healthy controls were included. Class-specific antibodies IgM, IgG, and IgA against three human cross-reactive and non-cross-reactive synthetic peptides from P. mirabilis-hemolysin (HpmB), urease C (UreC), and urease F (UreF)-were performed in all subjects, using the ELISA method. RA patients had elevated levels of IgM, IgG, and IgA antibodies against HpmB and UreC Proteus peptide which are significantly different compared to healthy controls: p = 0.005, p < 0.001, and p = 0.003 and p = 0.007, p = 0.002, and p < 0.001, correspondingly. Also, elevated levels of IgM, IgG, and IgA antibodies against the UreF Proteus peptide-which are non-cross-reactive with human tissue antigens-were observed and their significant difference compared to healthy controls (p = 0.007, p < 0.001, p < 0.001). Anti-peptide antibodies in RA patients showed a significant correlation with rheumatoid factors (Rf), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP), especially when patients were divided into subgroups according to the receiving treatment. Greek RA patients present elevated levels of antibodies against P. mirabilis antigenic epitopes, such as in North European populations, albeit Greek RA patients presenting the cross-reaction antigen in a low percentage. These results indicate that P. mirabilis through the molecular mimicry mechanism leads to inflammation and damage of the joints in RA.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011513 Proteus mirabilis A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that is frequently isolated from clinical specimens. Its most common site of infection is the urinary tract.
D005260 Female Females
D006115 Greece A country in southern Europe, bordering the Aegean Sea, Ionian Sea, and the Mediterranean Sea, between Albania and Turkey. The capital is Athens. Crete,Macedonia (Greece)
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Georgios Christopoulos, and V Christopoulou, and J G Routsias, and A Babionitakis, and C Antoniadis, and G Vaiopoulos
January 2007, Clinical and experimental rheumatology,
Georgios Christopoulos, and V Christopoulou, and J G Routsias, and A Babionitakis, and C Antoniadis, and G Vaiopoulos
January 1997, The Indian journal of medical research,
Georgios Christopoulos, and V Christopoulou, and J G Routsias, and A Babionitakis, and C Antoniadis, and G Vaiopoulos
November 2005, Rheumatology (Oxford, England),
Georgios Christopoulos, and V Christopoulou, and J G Routsias, and A Babionitakis, and C Antoniadis, and G Vaiopoulos
December 2020, International journal of molecular sciences,
Georgios Christopoulos, and V Christopoulou, and J G Routsias, and A Babionitakis, and C Antoniadis, and G Vaiopoulos
January 2004, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
Georgios Christopoulos, and V Christopoulou, and J G Routsias, and A Babionitakis, and C Antoniadis, and G Vaiopoulos
September 1995, Journal of medical microbiology,
Georgios Christopoulos, and V Christopoulou, and J G Routsias, and A Babionitakis, and C Antoniadis, and G Vaiopoulos
January 1997, Rheumatology international,
Georgios Christopoulos, and V Christopoulou, and J G Routsias, and A Babionitakis, and C Antoniadis, and G Vaiopoulos
January 2017, The Pan African medical journal,
Georgios Christopoulos, and V Christopoulou, and J G Routsias, and A Babionitakis, and C Antoniadis, and G Vaiopoulos
March 1999, The Journal of infection,
Georgios Christopoulos, and V Christopoulou, and J G Routsias, and A Babionitakis, and C Antoniadis, and G Vaiopoulos
October 1980, Journal of clinical microbiology,
Copied contents to your clipboard!